WHO Database Proposal Seen Benefiting Indian Generics
This article was originally published in PharmAsia News
Indian drug makers expect to benefit from a portion of an international agreement drafted by the World Health Organization establishing a centralized database of drugs and the countries in which patents have been secured for them. Generics makers see the database as helping to dispel assumptions by some non-governmental organizations that a drug under patent in one country is protected in all nations. The head of the Indian Pharmaceutical Alliance noted that most multinational drug makers seek patents for their products in only 50 to 60 countries. (Click here for more
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.